gener ep pro forma estim
initi coverag outperform rate price target base
elanco top-tier posit attract anim health market improv product
portfolio earli stage margin improv drive leverag ep growth
signific opportun stabl annual growth visibl anim
market driven global demand safe protein uptick new companion
anim drug elanco anim health compani decad experi
strong reput veterinari market one publicli trade larg
anim health compani elanco offer investor opportun particip
past sever year elanco build strong base food anim
health develop diversifi anim health portfolio focu faster growth
area companion anim prevent therapeut medicin poultri fish
product vaccin parasiticid develop effort nutrit antibiot
altern support estim revenu compound-annual-growth-rate gain
top-lin growth expect low end rang due
tough comparison wind-down strateg exit
conjunct shift faster growth area elanco embark oper
improv plan sever larg acquisit past year neg
impact margin focus plan place manufactur sg drive
oper margin expans estim
turn fuel estim ep compound-annual-growth-rate
sinc ipo septemb stock increas trade
ep compar outperform price-to-earnings multipl
price ep gear upsid potenti revenu ep
product portfolio/top line transit margin improv gain traction
pleas see page report import disclosur
signific opportun stabl annual growth visibl anim
market driven global demand protein uptick new companion anim
drug elanco anim health compani decad experi strong
reput veterinari market one publicli trade larg anim health
compani elanco offer investor opportun particip attract
plan remain ownership
sale compound-annual-growth-rate
ep compound-annual-growth-rate
faster expect
emerg signific product
pipelin
greater expect profit
effici improv take longer
less meaning
elanco spun-out septemb public stand-alone compani ipo
lilli retain ownership part lilli elanco anim
health busi sinc elanco largest compani global anim health
market sale brand sale countri
elanco spun-out septemb public stand-alone compani ipo
lilli retain ownership part lilli elanco
anim health busi sinc elanco largest compani global
anim market estim sale brand
sale countri second largest stand-alon publicli trade pure-play
anim health compani next zoeti
believ anim health market attract given steadi long-term growth
estim driven ww demand safe afford protein expect
uptick new companion anim product reach market believ
compani global market posit improv portfolio posit
least match industri sale growth rate exclud impact currenc
histor elanco view global leader medic feed addit
growth promot product howev past year elanco began
reposit leader area reflect current demand futur
opportun includ shift companion anim product diseas
prevent therapeut focus approach product anim
product emphasi poultri aquacultur develop safer
altern keep anim healthi promot effici
elanco oper margin pressur three larg acquisit
lohmann novarti anim health bi vetmedica elanco implement
extens plan improv cost structur initi result encourag oper
margin improv improv
expect margin reach drive
estim ep compound-annual-growth-rate
view key risk continu success transit new growth area
particularli given tough y/i revenu compar execut margin
improv initi abil navig investor expect addit
vagari anim market weather diseas polit issu significantli
influenc quarterli trend lilli ownership also repres overhang
expect lilli address issu
stock trade estim ep septemb
ipo price target impli ep multipl estim ep
reflect upsid potenti revenu ep well premium opportun
invest attract anim health market
ww anim health market estim grow annual
market broken product anim companion anim product food
anim primarili livestock includ cattl beef dairi swine poultri sheep
goat farm fish product market matur demand protein
emerg market key driver growth opportun provid safe protein
without addit offer longer term potenti weather diseas outbreak polit
market economi also influenc trend companion anim primarili dog
cat also hors expect sizabl influx new product mainli human drug
modifi pet use may soon enter market drive stronger growth compar
product segment increas medic pet pet live longer also
support growth may anim health market updat addit
axxiom consult cowen compani estim
top seven anim health compani annual sale least
repres nearli total ww sale top five compani are/wer part larg
pharma compani divers product mix although top
compani greater exposur product anim histor
larger market opportun expect mix shift toward companion anim
given expect growth opportun new product elanco fourth largest
anim health compani estim sale
compani data cowen compani
past decad elanco slowli transit food anim compani
diversifi anim health compani intern develop
acquisit elanco market brand well repres across mani
therapeut area product companion anim elanco largest singl
 demand safe protein need antibiot altern beef pork poultri farm biolog roll mani unmet need innov acceler growth per annum driven companionu rowcommentszoeti market leader new product boost sale growth fx impact minim ingelheim sni merial acquir boost marketmerck bravecto help sale ou acquisit boost spun lilli novarti ah acquir jan advantag account sale total sale ex fxceva pvt french co merial swine cattl vaccin acq french co sale ex fx ex fx fx boost eu compani fx less factor report growth privat companygeograph mixproduct sale mixww sale mm cowen
product rumensin ionophor antibiot cattle/swin account
approxim sale next four largest product
trifexi heartworm dog maxiban ionophor poultri denegard share
class antibiot swine tylan premix share class antibiot cattl swine
poultri account revenu detail product list
provid appendix
elanco focus three segment companion anim prevent companion
anim food anim futur protein segment
expect grow remain segment rumin swine
remain largest sale categori may focu develop
estim compound-annual-growth-rate lead total sale compound-annual-growth-rate report
includ strateg exit
elanco cowen compani estim
mix shift higher growth area expect boost percentag sale
target segment current level howev
increas companion anim sale two target area dog
cat total compani mix companion anim expect chang
fa futur protein segment includ grow poultri fish busi
well develop nutrit product food anim
compani data cowen compani estim
segmentdescriptionkey preventionparasiticid vaccin dog catsinterceptor credelio trifexi duramun therapeuticstherapeut medicin cat dog mainli chronic diseasesgallipr onsior deramaxx osurnia fortekor anim futur protein healthproduct poultri aquacultur nutrit maxiban monteban avipro clynav imvixa anim rumin swinefe addit diseas prevent product cattl swine rumensin tylan vira shield denagard exclud strateg exitsrevenu mm elanco mix target segment vs totaltarget mix companion anim vs food totalfood cowen
ca diseas prevent includ broad portfolio parasiticid protect
flea tick worm vaccin dog cat parasiticid credelio canin
oral interceptor canin oral heartworm approv use puppi
week elanco see key develop earli custom relationship elanco
also expand distribut new channel includ internet retail store
parasiticid made inroad altern non-veterinari set
boehring ingelheim launch first canin oral chewabl flea tick prevent
product nexgard afoxolan octob sinc three oral
option launch mrk bravecto flurolan simparica sarolan
recent elanco credelio lotilan earli compar topic
liquid collar oral product receiv favor due good
effect eas use topic product prevent bite requir
anim bitten messi smelli typic requir dri period
contact children/oth pet must avoid hurt
owner complianc oral estim account
ww market product
compani look life cycl manag success oral product
merck bravecto spot-on solut avail cat dog
eu also week durat action zoeti stronghold selamectin
sarolan merck bravecto fluralan moxidectin first two
combin product util respect oral agent topic spot-on
solut cat provid protect and/or treatment select extern
flea tick intern parasit heartworm roundworm hookworm stronghold
also treat ear mite lice expect compani develop addit
combin product dog cat well improv formul
elanco expect competit canin oral tripl combin flea tick worm
approv launch neg impact elanco sale ca
prevent segment approxim
model sync guidanc howev feel project may
overst think unlik oral tripl market
remain seen new combin fulli accept
veterinarian competit product may elanco pipelin
product label compani data cowen compani
ca includ number product treatment pain osteoarthr
oa pain gallipr ear infect osinur cardiolog fortek
dermatolog atopica elanco focu build portfolio emphasi
chronic condit pain dermatolog intern develop collabor
april elanco acquir exclus ww licens right gallipr
antagonist aratana up-front potenti mileston
payment co-promot fee royalti aratana co-promot
 gallipr approv march offer new oral
option nsaid safeti concern limit chronic use manag canin
osteoarthr pain gallipr launch earli sale disclos
appear strong least meet expect oa market
estim approxim gallipr licens agreement
provid addit depth elanco companion anim portfolio access larg
fa fp current includ vaccin nutrit enzym animal-onli antibiot
primarili poultri fish develop focus nutrit health product
promot food anim health improv product effici enzym
probiot prebiot nutritional-bas product would potenti provid
bravecto nexgard bi simparica credelio dosageeveri month monthlymonthlymonthlyg foodwith with/without with/without withminimum mo week mo weeksminimum weight lb lb lb lb time start kill flea hour hour hour hoursflea ctenocephalid felisxxxxtick amblyomma americanum lone tick xxx amblyomma maculatum gulf coast tick -- -- -- dermacentor variabili american dog tick xxxx rhipicephalu sanguineu brown dog tick xxxx ixod scapulari black-legged/d tick xxxxu approv may octob februari januari approv march februari novemb april per everi week lone tick exposur base price on-lin pet-stor price vari dog weight packag size price vet offic may higher cowen
altern antibiot growth promot address increas
market demand safe protein without perceiv harm addit
poultri includ antibiot mostli animal-onli ionophor monesin
vaccin avipro poultri lowest cost protein solid steadi global
aquacultur includ vaccin clynav parasiticid imvixa farm fish
primarili salmon expand speci farm fish grow market
driven demand benefit rel captur fish
nutrit hemicel enzym feed supplement poultri swine product
develop includ enzym probiot prebiot
wide rang agents/med ad food/wat product
anim decad use control/prev infect bacteri parasit
gain creat muscl maintain feed integr increas debat
use addit particularli antibiot especi one also use human
beta-agonist zilpaterol ractopamin due potenti neg impact
human anim meat produc taken strong stanc
tyson antibiot initi believ time use growth
promot low-dos anti-infect beta-agonist declin
howev need healthi anim safe food decreas expect
product vaccin probiot non-med import antibiot
ionophor genet gain increas use product anim market
larg anim health compani respond need altern elanco
indic target initi antibiot altern develop
project
fa rumin swine includ rang product cattl sheep goat
mani market decad includ animal-onli antibiot ionophor rumensin
share class antibiot denagard tylan premix elanco share class antibiot
declin due vfd veterinari feed direct chang
market demand share class antibiot revenu flat
sale ou vs animal-onli antibiot grew
larg ou animal-onli antibiot repres
revenu vs anim antibiot sale
ionophor
elanco also provid extens non-product servic includ analyt technic
support analyt help produc evalu larg amount health product data
convert usabl inform improv anim health
productivity/profit elanco continu support segment go forward
signific new product develop part fa fp initi
seek altern maintain anim health
elanco lead product sale rumensin feed addit ionophor
animal-onli antibiot cattl improv feed effici control coccidiosi
commerci year patent year manag
expect gener rumensin potenti total impact
approxim total sale factor model
ractopamin contain product optaflexx paylean pressur
regulatori chang china market restrict use led
produc elimin use ractopamin
elanco rbst posilac recombin bovin somatatropin commerci
 almost year increas milk product lactat cow howev due
anim welfar issu report increas udder infect higher risk lame
reproduct problem possibl link human health concern rbst legal
eu canada japan rbst still allow fda abl
fulli valid health concern like pressur antibiot use similar
consum pressur rbst
march elanco announc shift strateg focu dairi
sold posilac busi relat manufactur facil new focu
develop product work dairi cow immun system
biolog mechan improv resist stress diseas therefor
natur aid lactat area interest elanco dairi cattl includ bovin
respiratori diseas brd caus respiratori distress reproduct
problem need still exist despit use vaccin mycoplasma caus
respiratori infect calv mastiti cow difficult treat
mycobacterium lead john chronic infect tb
treatment digest health look earli diseas prevent feed
addit enzym pre- probiot antibiot altern improv
imrestor pegbovigrastim coloni stimul factor approv march
reduc incid clinic mastiti first day lactat
periparturi dairi cow imrestor protein help cow natur immun
system around time calv howev imrestor commerci
suspend due narrow label constrain uptak elanco
evalu imrestor sever addit indic
new product launch revenu
anoth new product new chemic
entiti new combin signific line extens develop assum
approxim one-third product commerci elanco indic
 spend target three primari growth segment
elanco success complet number bolt-on acquisit year
round therapeut categori believ addit bolt-on transact
like target area provid therapeut geograph and/or scale benefit
current sale ou europ largest contributor skew
food anim geograph divers posit provid cushion weather
diseas polit vagari
compani data cowen compani estim
ca diseas prevent credelio oral dog interceptor oral chewabl heartworm/oth worm dogs/puppiesca gallipr oral antagonist oa pain dog osurnia gel ear infect dog dose regimenfa protein clynav salmon vaccin pancrea diseas imvixia sea lice control intepr animal-onli antibiot poultryrumin swine kavault feed addit coli scour diarrhea wean pig imrestor coloni stimul factor mastiti dairi cow sale suspend pursu indicationsdateacquisit amount anim naad food anim growth promot implant anim naad companion food anim product expand eu enzyme/fe effici anim naad global leader poultri anim primarili companion anim aquacultur boost global vetmedica companion anim middl east america cowen
anim health gener estim approxim off-pat drug
kol expect percentag remain fairli stabl despit fact
vast major veterinari drug patent rel small annual sale
vast major product absenc larg payor limit gener inroad
unlik human drug brand product declin precipit first year
gener launch estim impact anim health tend
prolong less steep zoeti estim impact brand
product sale time
elanco revenu product without patent protect
includ top product rumensin maxiban denagrad tylan premix elanco
experienc gener pressur ractomapin declin
impact magnifi market pressur use product manag
expect gener rumensin potenti total impact
approxim total sale factor model
elanco integr number acquisit recent year novarti anim
largest acquisit neg impact oper margin howev
sinc post novarti anim health acquisit elanco improv
oper effici estim save achiev ye
oper margin improv addit
expans tap
initi drive improv includ reduct manufactur site close
far headcount reduct employe elimin
sku approxim addit elanco plan reduc direct-sal
market less current switch primarili
gpm side elanco continu improv manufactur process reduc
manufactur footprint advanc lean initi consolid network
insourc project appropri pursu new procur process raw
materi sg side elanco implement steadi state organiz
design reduc overhead cost post termin servic agreement lilli
estim complet ye work improv salesforc
product elanco indic product initi progress
ep estim revenu growth
includ neg currenc impact estim gross margin increas
sg decreas increas drive uptick
oper margin net interest expens estim tax rate
share count
forecast ep revenu growth reflect
tough compar post launch credelio wind strateg exit
potenti competit impact ca parasiticid estim gpm improv
sg increas increas fuel increas
oper margin net interest expens expect declin
tax rate increas model assum share count
remain flat although may trend option exercis
forecast revenu growth year leverag annual
ep gain time-frame estim gpm increas
year oper margin increas year
estim net interest expens trend year
tax rate expect remain stabl approxim share count hold
flat although could trend exercis option estim ep
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
 companion anim parasiticid trifexi credelio other assum competit headwind companion anim gallipr food anim futur protein poultri fish cattlerumin beef dairi cattl swine assum gener rumensin line industri averagestrateg -- -- -- -- -- distribut agreement contact mfg equin producttot revenu growth possibl upsid pipelin local currenc ex revenu local currenc ex cowen
compani data cowen compani estim
compani data cowen compani estim
asset account current current properti plant intang long term long-term short-term debt account current current long-term defer incom long-term long-term current payabl current work cash debt cowen
compani data cowen compani estim
compani data cowen compani estim
assumpt outputequ share outstand gross margin oper interest incom tax work free dcf mm cowen
cowen compani
productindicationspeciesca diseas preventionbronchi shield iiivaccin vs adenoviru parainfluenza bordetella bronchiseptica bb dogsbronchi shield oralor vaccin vs bbdogscomforti spinosad topic dogscredelio lotilan oral tdogsduramunevaccin line vs distemp adenoviru parvoviru corona parainfluenza leptospira canicola otherdogsrabvacvaccin line vs rabi formul dogsfel-o-vaxvaccin line vs leukemia rhinoviru calciviru panleukemia chlamydiafel-o-guardvaccin line vs leukemia rhinoviru calciviru panleukemia chlamydiainterceptor milbemycin oxime/praziquantel oral prevent heartworm treat roundworm wormsdogsmilbemax milbemycin oxime/praziquantel oral prevent heartworm treat roundworm worm dogstrifexi spinosad/ milbemycin oxim oral prevent heartworm kill fleasdogsca therapeuticsatopica cyclosporin atop dermatitisdogsfortekor benazepril/ pimobendan congest heart failuredogsgallipr grapipr oa paindogsonsior robenacoxib post-op pain dogsosurnia terbinafine/ florfenicol/ betamethason otiti media ear infect dogsderamaxx deracoxib oa paindogssurolan miconazol polymyxin prednisolon otiti media ear infect dogsfa futur protein healthaviprovaccin line vs newcastl bronchiti cholera paramyxoviru bursal diseas salmonella other poultryclynavvaccin vs caus pancrea diseas salmonfishcoban/elancoban monensin ionophor anim antibiot prevent coccidiosispoultryhemicellenzym feed supplementpoultri swineimvixa lufenuron parasiticid prevent sea lice farm salmon fishmaxiban narasin/ nicarbazin ionophor anim antibiot prevent coccidiosispoultrysurmax/maxus/intepr avilamycin animal-onli antibiot prevent mortal caus necrot enteritispoultryfa rumin swinedenagard tiamulin share class antibiot treat swine dysenteri bacteri enteritisswineoptaflexx/paylean ractopamin beta adrenoreceptor agonist growth promotercattl swinepulmotil tilmicosin share class antibiot treat swine respiratori diseas bovin respiratori diseasecattl swinerumensin monensin ionophor anim antibiot feed product effici control coccidiosi cattl swine goatstylan premix tylosin share class antibiot control enteropathiesswin cattl vira shieldvaccin line vs variou bovin infectionscattl cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
abil transit product mix gener revenu growth success
pipelin continu execut oper improv plan weather/disease/
polit risk busi success independ compani
